FDA
- Status: approved
Fondaparinux background and low dose heparin (Fondaparinux background and low dose heparin) regulatory status in United States.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA has authorised it.
GlaxoSmithKline is the originator. The local marketing authorisation holder may differ — check the official source linked above.